Recurrent pregnancy loss thrombophilia

Clinical Laboratory

Volumn 53, Issue 5-6, 2007, Pages 309-314

  Di Micco, Pierpaolo ^a,b   D'Uva, Maristella ^b   Strina, Ida ^b   De Placido, Giuseppe ^b   Di Fiore, Rosanna ^b   Quaranta, Sandro ^b   Castaldo, Giuseppe ^b  

^a Internal Medicine Division   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 12; CARDIOLIPIN ANTIBODY; ENOXAPARIN; HEPARIN; HOMOCYSTEINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN;

ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; GENETIC POLYMORPHISM; HIGH RISK PREGNANCY; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; LOW DRUG DOSE; PATHOPHYSIOLOGY; PREGNANCY OUTCOME; PREGNANT WOMAN; REVIEW; SPONTANEOUS ABORTION; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ABORTION, HABITUAL; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PREGNANCY; PREGNANCY OUTCOME; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 34250852838     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Sarig G, Younis JS, Hoffman F, Lamir N, Blumenfeld Z, Brenner B. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002;77:342-7
2. Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001;86:104-1
3. Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, Inbal A. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 2002;17:1633-7
4. Prandoni P, Tormene D, Simioni P, Girolami A. Venous thromboembolism, fetal loss and preeclampsia in pregnant women with congenital thrombophilia. Clin Lab 2001;47:155-9
5. Abbate R, Lenti M, Fatim C, Gazzini A, Lapini I, Fedi S. L'ipercoagulabilità gravidica e puerperale. Haematologica 2003;88 (Suppl.7):1-2 [Italian]
6. Hathaway WE and Goodnight SH Jr. Thrombosis in pregnancy. In: Disorders of hemostasis and thrombosis. A clinical guide (Eds.) Hathaway WE, Goodnight HS Jr. New York: McGraw-Hill; 1993:430-6
7. de Boer K, Ten Cate JW, Sturk A, Borm JJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989;160:95-100
8. Di Micco P, D'Uva M, Strina 1, Mollo A, Amato V, Niglio A, De Placido G. The role of D-dimer as first marker of thrombophilia in women affected by sterility: implications in pathophysiology and diagnosis of thrombophilia-induced sterility. J Transl Med 2004;2:38
9. Colman-Brochu S. Deep vein thrombosis in pregnancy. MCN Am J Matem Child Nurs 2004;29:186-92
10. Robertson L, Wu 0, Langhorne P, Twaddle S, Clark P, Lowe GDO, Walker ID, Greaves M, Brenkel I, Rgan L, Greer IA. The Thrombosis: Risk and Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006;132:171-196
11. Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999;82:6-9
12. Martinelli I. Risk factors in venous thromboembolism. Throm Haemost 2001;86:395-403
13. Franchim M, Veneri D. Inherited thrombophilia: an update. Clin Lab 2005;51:357-65
14. Sanson BJ, Fierich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A, ten Cate JW, Prins MH. The risk of abortion and stillbirth in antithrombin-, protein C, and protein S deficient women. Thromb Haemost 1996;75:387-8
15. Pickering W, Marriott K, Regan L. G20210A prothrombin gene mutation: prevalence in a recurrent miscarriage population. Clin Appl Thromb Haemost 2001;7:25-8
16. Pihusch R, Buchholz T, Lohse P, Rubsamen H, Rogenhofe N, Hasbargen U. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 2001; 46, 124-31
17. Finan RR, Tamim H, Ameen G, Sharida HE, Rashid M, Almawi WY. Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population. Am J Hematol 2002;71:300-5
18. Reznikoff-Etievan MY, Cayol, V, Carbonne B, Robert A, Coulet F, Milliez J. Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. BJOG 2001;108:1251-4
19. Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, Bozzo M, Mannucci PM. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000;343: 1015-8
20. Rai R, Shlebak A, Cohen H, Backos M, Holmes Z, Marriott K. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001;16:961-5
21. Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappucci G, Vecchione G. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997;77:822-4
22. Hatzis T, Cardamakis E, Drivalas E, Makatsoris K, Bevan D, Pantos C. (1999). Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors. Eur J Contraceptive Reproductive Health Care 1999;4:135-144
23. Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998;128:1000-3
24. Pabinger I, Nemes L, Rintelen C, Koder S, Lechler E, Loreth RM. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematology J 2000;1:37-41
25. Lissak A, Sharon A, Fruchter O, Kassel A, Sanderovitz J, Abramovicic H. Polymorphism for mutation of cytosine to thymine at location 677 in the methylenetetrahydrofolate reductase gene is associated with recurrent early fetal loss. Am J Obstet Gynecol 1999;181:126-30
26. Wouters MG, Boers GH, Blom HJ, Trijbels FJ, Thomas CM, Borm GF. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993; 60:820-5
27. Nelen WLDM, van der Molen EF, Blom HJ, Heil SG, Steegers EAP, Eskes TKAB. Recurrent early pregnancy loss and genetic-related disturbances in folate and homocysteine metabolism. Brit J Hospital Med 1997;58:511-3
28. Fatini C, Gensini F, Battaglini B, Prisco D, Cellai AP, Fedi S. Angiotensin converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal loss susceptibility. Blood Coagul Fibrinolysis 2000; 11, 657-62
29. Raziel A, Kornberg Y, Friedler S, Schachter M, Sela BA, Ron-El R. (2001). Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. Am J Reproductive Immunol (Copenhagen) 2001;45:65-71
30. Makino A, Nakanishi T, Sugiura-Ogasawara M, Ozaki Y, Suzumori N, Suzumori K. No association of C677T methylenetetrahydrofolate reductase and an endothelial nitric oxide synthase polymorphism with recurrent pregnancy loss. Am J Reprod Ininumol 2004;52:60-6
31. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low molecular weight heparin versus unfractionated heparin. Fertil Steril 2005;83:684-90
32. Infante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Eng J Med 1991;325:1063-6
33. 2-glycoprotein I antibody in patients with recurrent fetal miscarriage. J Perinat Med 1998; 26(5), 384-9
34. Chakrabarti S, Bhunia C, Bliattacharya DK. The prevalence of antiphospholipid antibodies in cases of recurrent pregnancy loss. JAPI 1999; 47(5), 496-8.
35. Das I, Vasishta K, Dash S. Study of lupus anticoagulant in pregnant women with recurrent abortion. Aust N Z J Obstet Gynecol 1991;31:323-6
36. Asherson RA, Cervera R. "Primary", "secondary" and other variants of antiphospholipid syndrome. Lupus 1994;3:293-8
37. 2-glycoprotein I antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: Prevalence and clinical significance. Lupus 1996;5:587-92
38. De Carolis S, Caruso A, Ferrazzani S, Carducci B, De Santis L, Mancuso S. Poor pregnancy outcome and anticardiolipin antibodies. Fetal Diagnostic Therapy 1994;9:296-9
39. Blumenfeld Z, Weiner Z, Lorber M, Sujov P, Thaler I. Anticardiolipin antibodies in patients with recurrent pregnancy wastage: treatment and uterine blood flow. Obstet Gynecol 1991;78:584-9
40. Brown HL. Antiphospholipid antibodies and recurrent pregnancy loss. Clin Obstet Gynecol 1991;34:17-26
41. 2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003;62:540-3
42. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11
43. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006:4:295-306
44. Braulke I, Priggmayer M, Melloh P, Hinney B, Kostering H, Gunther H. Factor XII (Hageman) deficiency in women with habitual abortion: new subpopulation of recurrent aborters? Fertil Steril 1993; 53, 98-101
45. Jones DW, Mackie IJ, Gallimore MJ, Winter M. Antibodies to factor XII and recurrent fetal loss in patients with the anti-antiphospholid syndrome. Br J Haematol 2001; 113, 550-552
46. D'Uva M, Strina, I, Mollo A, Ranieri A, De Placido G, Di Micco P. Acquired factor XII deficiency in a woman with recurrent pregnancy loss: working on a differential diagnosis in a single case. J Transl Med 2005; 3:43
47. Nishiguchi T, Kobayashi T. Antiphospholipid syndrome: characteristic and obstetrical management. Curr Drug Targets 2005; 6: 593-605
48. 2-glycoprotein I and annexin V. Reproduction 2006;131:817-822
49. 2-glycoprotein 1 in the assessment of antiphospholipid syndrome. Blood Coagul Fibrinolysis 2003; 14:1-2
50. Dossenbach-Glaninger A, von Trotsenburg M, Krugluger W, Dossenbach MR, Oberkanins C, Huber J, Hompeier P. Elevated coagulation factor VIII and the risk for maternal early pregnancy loss. Thromb Haemost 2004;91:694-9
51. Tal J, Schliamer LM, Leibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 1999;14:1624-7
52. 5). Thromb Haemost 1999;81:891-9
53. Greer IA. Epidemiology, risk factors and prophylaxis of venous thromboembolism in obstetrics and gynaecology. Clin Obstet Gynaecol 1997;11:403-30
54. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353:1258-1265
55. Di Micco P, D'Uva M. The role of low molecular weight heparin to prevent miscarriage in thrombophilia women. Thromb Haemost 2005;94:897-8
56. Bertina RM, Rosendaal FR. Venous thrombosis - the interaction of gene and environment. N Engl J Med 1998;338:1840-1
57. Greer IA. The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med 2000;342:374-80
58. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1998;114(Suppl. 5):524S-530S
59. Brill-Edwards P. Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, Geerts W, Kovacs M, Weitz JI, Robinson KS, Whittom R, Couture G. Safety of withholding heparin in pregnant women with history of venous thromboembolism. N Engl J Med 2000;343:1439-44
60. Bates SM, Ginsberg JS. Pregnancy and deep vein thrombosis. Semin Vasc Med 2001;1:97-104
61. Phillips OP. Venous thromboembolism in the pregnant woman. J Reprod Med 2003;48:921-8
62. Bates SM. Treatment and prophylaxis of venous thromboembolism during pregnancy. Thromb Res 2002;108:97-106
63. Braneazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 1995; 173:1240-5
64. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83:693-7
65. Sarig G, Blumenfeld Z, Leiba R, Lanir Nand Brenner B. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 2005; 94:980-5
66. Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005;3:227-9
67. Brenner B, Hoffman R, Carp H, Dulitsky M and Younis J for the LIVE-ENOX Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX Study. J Thromb Haemost 2005;3: 1-2
68. Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, Ensom MH. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004;26:729-34
69. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight-heparin versus unfractionated heparin. Fertil Steril 2005;83:684-90
70. Ruffatti A, Favaro M, Tonello M, De Silvestro G, Pengo V, Fais G, Suma V, Chiarelli S, Todesco S. Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. Lupus 2005;14: 120-8